Siemens Healthineers Stock Plummets to 52-Week Low Amid Weak Forecasts
Siemens Healthineers has faced a sharp drop in its stock price since early 2026. The medical technology firm, known for its advanced imaging and diagnostic equipment, saw shares tumble to between €35.66 and €36.96 by late March—a new 52-week low. Investors appear concerned over weak second-quarter forecasts and broader structural challenges in the healthcare sector.
The decline contrasts with the performance of its parent company, Siemens, whose stock fell just 5.3% year-to-date to around €228. While analysts remain divided, the sell-off reflects growing uncertainty about future demand for high-end medical devices. The stock's downward trend accelerated as Deutsche Bank cut its price target to €42, citing expectations of only 3% revenue growth and a 16% drop in profits. The bank also downgraded its rating to 'Hold', adding to investor unease. Despite this, other firms like Barclays and RBC have kept their targets at €55, suggesting potential for recovery if market conditions improve.
Beyond company-specific issues, broader healthcare policy shifts are adding pressure. A political initiative from North Rhine-Westphalia proposes stricter primary care rules, requiring patients to see a general practitioner before specialist referrals. If rolled out nationwide from 2028, this could reduce demand for Siemens Healthineers' specialist-focused equipment. Additionally, ongoing debates over statutory health insurance funding may lead to spending freezes, further limiting hospital investments in new technology.
The stock's year-to-date losses now approach 20%, underperforming both its parent company and many peers. While analyst consensus still points to an average target of €55, the gap between current prices and expectations highlights deepening concerns about the firm's near-term outlook. Siemens Healthineers now trades near its lowest point in a year, with shares hovering around €36. Weak forecasts, policy risks, and investor caution have driven the decline. Whether the stock rebounds will depend on upcoming financial results, healthcare funding decisions, and whether the proposed primary care reforms gain traction across Germany.
